Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

Documenti analoghi

• Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells
  di: Horn, Moritz, et al.
  Pubblicazione: (2018)
• Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
  di: Dou, Q. Ping, et al.
  Pubblicazione: (2014)
• Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
  di: Driessen, Christoph, et al.
  Pubblicazione: (2018)
• The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma
  di: Brayer, Jason, et al.
  Pubblicazione: (2017)
• Hexosamine Pathway Activation Improves Protein Homeostasis through the Integrated Stress Response
  di: Moritz Horn, et al.
  Pubblicazione: (2020-03-01)